|
|
Article: Stem Cell Therapeutics Corp. and Medicon A/S Initiate Dosing of Patients in Phase I Study of NTx(TM)-265.
- Article from:
- PR Newswire Europe
- Article date:
- November 29, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CALGARY, Canada, November 29 /PRNewswire/ --
TSX-Venture Exchange: SSS
Stem Cell Therapeutics Corp. ("SCT") is pleased to announce completion of screening and initiation of dosing in its Phase I Clinical Study of NTx(TM)-265, SCT's program for the treatment of stroke. This Phase I Clinical Trial is currently being conducted on SCT's behalf by Medicon A/S ("Medicon") of Birkerod, Denmark.
The Phase I trial is designed to characterize the pharmacokinetic profile of two currently marketed drugs, identified by SCT as effective in non- clinical models of stroke. As previously reported, the Phase I study subjects will be dosed in two groups staggered ...